IRVINE, Calif. and TELTOW, Germany, June 7, 2018 /PRNewswire-PRWeb/ -- OD-OS, the global
Several studies have presented evidence on the effectiveness of navigated microsecond pulsing with NavilasŪ, e.g. for treating focal leakage in chronic central serous chorioretinopathy (CSCR) 1-3.
"In a recent study, we have compared the effectiveness of navigated microsecond pulsing and photodynamic therapy in treating CSCR," says Dr. Jay Chhablani from LV Prasad Eye Institute in India a retina physician who had practiced retinal care at institutions in Europe, and the USA. "The results are the first to demonstrate that the use of navigated microsecond pulse laser therapy produces statistically significant improvements in treatment outcomes for eyes with CSCR. We have seen better visual acuity, a significant reduction in central macular thickness, and for almost 2/3 even complete resolution of the subretinal fluid. Therefore, this can be a cost-effective, less damaging therapy for CSCR cases." 1
Tissue-friendly laser treatment with a train of extremely short microsecond pulses is an increasingly popular concept in retinal care. Rather than photocoagulation, this treatment aims to use photothermal stimulation for diseased retinal areas, preserving cell function and avoiding retinal scarring. More and more retinal physicians are integrating this approach in their daily clinical routines, and many patients are becoming aware of this gentle treatment option.
The NavilasŪ 577s software release 3.4 offers enhanced digital visualization for handling combined navigated microsecond pulsing and photocoagulation treatment plans, thus enhancing the unique capabilities of tissue-friendly care with NavilasŪ:
Watch video: https://www.youtube.com/watch?v=JMDFCAP4rQ8
"Since the launch of the compact NavilasŪ 577s Laser System, we have seen true excitement from retinal experts in the market. We're glad that we have brought a new paradigm of retinal laser care to routine use in many renowned clinics and private practices worldwide," said OD-OS Managing Director Dr. Winfried Teiwes. "With this software release, we demonstrate our commitment to continued development and optimization of this novel digital technology with the goal to offer highly accurate and efficient laser application at enhanced patient comfort."
About NavilasŪ: NavilasŪ laser systems enable physicians to digitally pre-plan the entire laser therapy on fundus images as well as on third-party diagnostic images, and to precisely execute this therapy plan with the help of computer guidance. Unlike any other retina laser, NavilasŪ offers focal treatments without a contact lens and infrared illumination for more patient comfort. A large field of view and assisted pattern positioning greatly improve speed in panretinal and focal treatments.
About OD-OS: OD-OS GmbH, a privately-held medical device company founded in 2008 with offices in Teltow, Germany, and Irvine, CA, is dedicated to the development and commercialization of navigated imaging and laser treatment technology used to facilitate the advanced treatment of retinal eye diseases, many of which may lead to permanent blindness. Visit http://www.od-os.com for more details.
For further information, please contact:
Stefanie Gehrke, Director Marketing | stefanie.gehrke(at)od-os.com, +49 (172) 3808 537 OD-OS GmbH | Warthestr. 21 | 14513 Teltow | Germany | Phone.: +49 (3328) 312 82 195 info(at)od-os.com | http://www.od-os.com
Visit the Navilas Team at DOC in Nürnberg, booth I7 and WOC in Barcelona, Booth 3009.
1 Comparison of Photodynamic Therapy and Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy. Ntomoka, Cyprian Gabriel, Bindu Rajesh, Gachago Muchai Muriithi, Abhilash Goud, and Jay Chhablani. Eye, February 12, 2018. PubMed PMID: 29429986
2 Retinal Physician - Initial Experiences With Yellow Navigated Laser and Microsecond Pulses in Patients With DME. Kernt, Marcus "Retinal Physician. Accessed November 22, 2017. link
3 Microsecond Yellow Laser for Subfoveal Leaks in Central Serous Chorioretinopathy. Ambiya, Vikas, Abhilash Goud, Annie Mathai, Padmaja Kumari Rani, and Jay Chhablani. Clinical Ophthalmology (Auckland, N.Z.) 10 (August 11, 2016): 1513. PubMed PMID: 27570446
Subscribe to our Free Newsletters!